For research use only. Not for therapeutic Use.
Vandetanib（Cat No.:A000467）is a tyrosine kinase inhibitor that targets multiple receptors, including vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) kinase. It is primarily used to treat advanced medullary thyroid cancer by inhibiting tumor growth, angiogenesis, and metastasis. Vandetanib’s ability to block these key signaling pathways makes it effective in slowing cancer progression and improving patient outcomes. Additionally, it has shown promise in clinical trials for other cancers. Vandetanib’s multitargeted approach offers a valuable option for treating tumors driven by these pathways.
| Catalog Number | A000467 |
| CAS Number | 443913-73-3 |
| Molecular Formula | C₂₂H₂₄BrFN₄O₂ |
| Purity | ≥95% |
| Target | VEGFR |
| Solubility | Limited solubility |
| Storage | 3 years -20C powder |
| IUPAC Name | N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine |
| InChI | InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27) |
| InChIKey | UHTHHESEBZOYNR-UHFFFAOYSA-N |
| SMILES | CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC |
| Reference | 1. Duplomb S, Benoit A, Mechtouff-Cimarelli L, Cho TH, Derbel O, Peix JL, de la Fouchardière C. Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer. *J Clin Oncol*. 2011 Dec 12. [Epub ahead of print] PubMed PMID: 22162581. 2. Langmuir PB, Yver A. Vandetanib for the Treatment of Thyroid Cancer. *Clin Pharmacol Ther*. 2011 Dec 7. doi: 10.1038/clpt.2011.272. [Epub ahead of print] PubMed PMID: 22158569. 3. Ernesto S, Arpin D, Nesme P, Pérol M. Diffuse Interstitial Lung Disease Linked to Vandetanib. *Clin Lung Cancer*. 2011 Nov 29. [Epub ahead of print] PubMed PMID: 22133289. 4. Koch L. Pharmacotherapy: Vandetanib—a new therapeutic option in advanced medullary thyroid cancer. *Nat Rev Endocrinol*. 2011 Nov 15;8(1):1. doi: 10.1038/nrendo.2011.198. PubMed PMID: 22083086. 5. Solomon B, Rischin D. Progress in Molecular Targeted Therapy for Thyroid Cancer: Vandetanib in Medullary Thyroid Cancer. *J Clin Oncol*. 2011 Oct 24. [Epub ahead of print] PubMed PMID: 22025155. 6. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. *J Clin Oncol*. 2011 Nov 21. [Epub ahead of print] PubMed PMID: 22025146. 7. Qi WX, Tang LN, He AN, Shen Z, Yao Y. The role of vandetanib in the second-line treatment for advanced non-small-cell lung cancer: a meta-analysis of four randomized controlled trials. *Lung*. 2011 Dec;189(6):437-43. Epub 2011 Oct 11. PubMed PMID: 21986852. 8. Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. *Korean J Ophthalmol*. 2011 Oct;25(5):355-7. Epub 2011 Sep 20. PubMed PMID: 21976946; PubMed Central PMCID: PMC3178773. 9. Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. *Br J Cancer*. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4. PubMed PMID: 21970874. 10. Saletti P, Sessa C, De Dosso S, Cerny T, Renggli V, Koeberle D. Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma. *Oncology*. 2011;81(1):50-4. Epub 2011 Sep 15. PubMed PMID: 21921646. |
